Everything to Know about Macro and Markets Stocks clocked in large weekly gains, returning to positive territory year-to-date ...

FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

At the crossroads of innovation and equity, Josette Gbemudu and Merck are helping rewrite the narrative for breast cancer ...

The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...

At Gilead, we’re advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them ...

But new research published in JAMA Pediatrics found distinct patterns of long COVID symptoms in young children. Researchers ...

Gilead Sciences Inc. has synthesized indoline compounds acting as DNA helicase-primase complex (human herpes simplex virus) and viral replication inhibitors reported to be useful for the treatment of ...

Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Gilead Sciences Inc. closed 7.92% below its 52-week high of $119.96, which the company achieved on March 10th.

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.